LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Inc (LBRX)
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate Affairs and Lindsay Beaupre, the new Senior Vice President of People and Culture of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on January 9, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Ms. Rose and Ms. Beaupre entering into employment with LB Pharmaceuticals. Ms. Rose and Ms. Beaupre received options to purchase 100,000 and 75,000 shares of LB Pharmaceuticals’ common stock, respectively. The options carry a ten-year term and an exercise price per share equal to $20.73, which was the closing price of LB Pharmaceuticals’ common stock on the date of grant, and vests
Show less
Read more
Impact Snapshot
Event Time:
LBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBRX alerts
High impacting LB Pharmaceuticals Inc news events
Weekly update
A roundup of the hottest topics
LBRX
News
- LB Pharmaceuticals (NASDAQ:LBRX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.MarketBeat
- LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture [Yahoo! Finance]Yahoo! Finance
- LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & CultureGlobeNewswire
- LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
LBRX
Sec Filings
- 12/31/25 - Form SCHEDULE
- 12/11/25 - Form 4
- 11/18/25 - Form 3
- LBRX's page on the SEC website